Table 3.
Characteristics of patients with worsening pre-existing PNS after immunotherapy (cohort 1) or newly diagnosed PNS following immunotherapy (cohort 2)
| Outcome of patients with worsening or newly diagnosed PNS | Cohort 1 (pre-existing PNS) n = 8 patients with PNS worsening |
Cohort 2 (newly diagnosed PNS) n = 16 patients |
Total n = 24 patients |
|---|---|---|---|
| Time from initiation of immunotherapy to PNS worsening (cohort 1) or new diagnosis of a PNS (cohort 2), median (range), in months | 0.9 (0.5–2.8) | 1.6 (0.5–6.4) | 1.4 (0.5–6.4) |
| Antitumor response at time of worsening or newly diagnosed PNS, n (%) | |||
| - CR | 2 (25) | 1 (6) | 3 (13) |
| - PR | 2 (25) | 5 (31) | 7 (30) |
| - SD | 2 (25) | 10 (63) | 12 (50) |
| - PD | 2 (25) | 0 | 2 (8) |
| Best overall antitumor response | |||
| - CR | 2 (25) | 1 (6) | 3 (13) |
| - PR | 3 (38) | 5 (31) | 8 (33) |
| - SD | 1 (13) | 8 (50) | 9 (38) |
| - PD | 2 (25) | 2 (13) | 4 (17) |
| Impact of PNS on immunotherapy, n (%) | |||
| - temporary discontinuation | 2 (25) | 4 (25) | 6 (25) |
| - permanent discontinuation | 5 (62) | 9 (56) | 14 (58) |
| - no discontinuation | 1 (13) | 3 (19) | 4 (17) |
CR Complete response, CTCAE Common Terminology Criteria for Adverse Events, PD Progressive disease, PNS Paraneoplastic syndrome, PR Partial response, SD Stable disease